[Use of Legalon in non-alcoholic fatty liver disease].
The article presents the current understanding of the etiology, pathogenesis of nonalcoholic fatty liver disease, its basic forms, risk factors, prevalence and clinical course. Shows the data of research on the effectiveness of purely herbal product Legalon, in the treatment of non-alcoholic fatty liver disease. The 2-month course of treatment was underwent in the research team, on that background there was noted positive dynamics: cropped asthenic syndrome, pain and heaviness in the right hypochondrium, dyspepsia. In assessing of the biochemical parameters was shown a significant decrease in serum transaminases, gamma-glyutamiltransaminazy level.
Buturova
L I
LI
Tsybizova
T A
TA
Kalinin
A V
AV
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D001247:Asthenia / Q000139:chemically induced; D004415:Dyspepsia / Q000139:chemically induced; D005234:Fatty Liver / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced; D012838:Silymarin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000975:Antioxidants; D012838:Silymarin